Novo Nordisk posts results of Phase 3 KBP-5074 trial in uncontrolled hypertension and CKD
The study enrolled 666 participants and began on November 5, 2021, with primary completion on January 30, 2024. The trial was terminated and the results were first posted on ClinicalTrials.gov on November 4, 2026.
Primary source
ClinicalTrials.gov results record, November 4, 2026
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Read the source: Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation